ProfileGDS5678 / 1452176_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 91% 90% 93% 91% 91% 92% 91% 90% 91% 92% 92% 89% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.5342292
GSM967853U87-EV human glioblastoma xenograft - Control 27.5594791
GSM967854U87-EV human glioblastoma xenograft - Control 37.2252190
GSM967855U87-EV human glioblastoma xenograft - Control 48.0121193
GSM967856U87-EV human glioblastoma xenograft - Control 57.3976791
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1026891
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.3464692
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.3207691
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1628190
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.5395491
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.5329792
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6407392
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9393889
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3855391